AB Science S.A. (EPA:AB)
1.046
+0.114 (12.23%)
May 14, 2026, 5:37 PM CET
AB Science Revenue
In the year 2025, AB Science had annual revenue of 1.17M EUR with 9.51% growth. AB Science had revenue of 515.00K in the half year ending June 30, 2025, with 14.96% growth.
Revenue
1.17M
Revenue Growth
+9.51%
P/S Ratio
69.46
Revenue / Employee
28.53K
Employees
36
Market Cap
71.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17M | 102.00K | 9.51% |
| Dec 31, 2024 | 1.07M | 102.00K | 10.52% |
| Dec 31, 2023 | 970.00K | 12.00K | 1.25% |
| Dec 31, 2022 | 958.00K | -649.00K | -40.39% |
| Dec 31, 2021 | 1.61M | 24.00K | 1.52% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 47.35B |
| EssilorLuxottica Société anonyme | 28.49B |
| Ipsen | 3.93B |
| Sartorius Stedim Biotech | 2.98B |
| Eurofins-Cerep | 38.86M |
| Klea Holding | 22.17M |
| ABL Diagnostics Société anonyme | 6.23M |
| Adocia | 3.85M |
AB Science News
- 1 day ago - AB Science reports its revenues for the year 2025 and provides an update on its activities - GlobeNewsWire
- 1 day ago - Q1 2026 Fingerprint Cards AB Earnings Call Transcript - GuruFocus
- 14 days ago - AB Maintained by TD Cowen -- Price Target Lowered to $39.00 - GuruFocus
- 15 days ago - AB Maintained by Barclays -- Price Target Lowered to $39.00 - GuruFocus
- 15 days ago - AB Science announces the successful completion of a EUR 3.2 million private placement - GlobeNewsWire
- 17 days ago - AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors - GlobeNewsWire
- 23 days ago - AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients - GlobeNewsWire
- 27 days ago - AB Maintained by Barclays -- Price Target Lowered to $40 - GuruFocus